First, we demonstrated using transcriptional analysis that IL2RB mRNA expression is associated with increased infiltration of immune cells such as T cells and cytotoxic lymphocytes, which are known to be associated with improved outcomes in CRC patients and the good-prognosis immune CMS1 molecular subtype. Here, IL2RB is linked to colorectal carcinoma.